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Loki zupa (Luooukezupa) decoction 
reduced airway inflammation in an 
OVA-induced asthma mouse model
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Abstract 
Background: Loki zupa (Luooukezupa) decoction, consisting of the roots of Hyssopuscuspidatus Boriss (Shenxiangcao) 
and Irishalophila Pall root (Yuanweigen), is commonly used in Uygur medicine to treat asthma. However, the mode of 
action of this material has yet to be elucidated. This study aims to investigate the effects of Loki zupa decoction on the 
airway inflammation of an ovalbumin (OVA)-induced asthma mouse model.
Methods: Mice were divided into normal control (NC), asthma (A), high, medium and low doses of Loki zupa decoction (L 
14.0, L 7.0, L 3.5), water extract (LW), n-butanol extract (LN), ethyl acetate extract (LE) and dexamethasone (DEX) groups. Anti-
asthmatic model was induced by OVA sensitization and challenged using BALB/c mice. Airway hyperresponsiveness (AHR) 
toward methacholine (Mch) was assessed using Buxco equipment. Lung inflammation was measured by hematoxylin and 
eosin staining and bronchoalveolar lavage fluid (BALF) cell count and classification. Inflammatory cytokines in BALF and 
serum were analyzed by Bio-Plex assay, and mRNA levels were investigated by qPCR analysis. The roots of H. Boriss (250 g) 
and I. Pall (250 g) were decocted, concentrated and diluted to 14.0, 7.0 and 3.5 g crude herb/kg body weight. The LW, LN 
and LE of the Loki zupa decoction were prepared and diluted to a dose equivalent to 7 g of crude herb/kg body weight.
Results: Loki zupa decoction and its extracts significantly attenuated the AHR towards Mch (all P < 0.05). Treatment 
with Loki zupa decoction and its extracts relieved the infiltration of inflammatory cells in and around the airways, 
and reduced the total white blood cell (all P < 0.05), neutrophil (all P < 0.05), monocyte (all P < 0.05) and eosinophil 
(all P < 0.05) counts in the BALF. The BALF samples collected from the mice treated with the Loki zupa decoction and 
its extracts had lower levels of IL-1β (all P < 0.05), TNF-α (all P < 0.05), IL-2 (all P < 0.05), IL-4 (P = 0.047) and IL-5 (all 
P < 0.05). The serum samples of these mice also had lower IL-1β (all P < 0.05), TNF-α (all P < 0.05), IL-4 (all P < 0.05) and 
IL-5 (all P < 0.05) levels and higher levels of IFN-γ (P < 0.001) compared with the OVA-induced asthma mouse model. 
qPCR analysis revealed that Loki zupa decoction and its extracts inhibited mRNA expression of IL-4 (all P < 0.05), IL-5 
(all P < 0.05) and IL-13 (all P < 0.05) and promoted mRNA expression of IFN-γ (all P < 0.05) in asthmatic mice.
Conclusion: Loki zupa decoction reduced AHR, attenuated airway inflammation, promoted Th1 and suppressed Th2 
cell functions in an OVA-induced asthma mouse model.
© 2016 Wei et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Asthma is one of the most prevalent respiratory diseases in 
the world, and the prevalence of this disease is increasing 
on an annual basis [1]. Asthma is characterized by the 
inflammation of the airways, with the airways also becom-
ing hyperresponsive. Furthermore, the inflammatory cells 
can infiltrate the airways, resulting in the secretion of 
related pro-inflammatory mediators [2]. Inhaled corticos-
teroids are currently the most effective drugs available for 
the treatment of asthma [3, 4]. However, the use of these 
drugs is often accompanied by undesirable side effects.
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The Th2-driven inflammation of the eosinophilic air-
ways is responsible for upto 50 % of all cases of asthma, 
and is generally considered to be the major pathogenetic 
factor in this disease [4–6]. Asthmatic patients typically 
have elevated levels of Th2 cytokines in their BALF and 
bronchial mucosa [7]. It is well known that Th2-acti-
vated cells orchestrate pulmonary immune responses 
and mediate the inflammation of lung tissues, as well as 
airway hyperresponsiveness [8–10]. Th1-activated cells 
also inhibit the inflammation of asthmatic airways [11]. 
It is noteworthy that mice deficient in the Th1-type tran-
scription factor T-bet develop spontaneous AHR and 
augmented airway eosinophilia [12]. The immunomodu-
lation of the Th1/Th2 imbalance encountered in asthma 
patients is therefore considered to be a practical strategy 
for controlling asthma [11].
Loki zupa (Luooukezupa) decoction, which consists of 
a 1:1 mixture (w/w) of the roots of Hyssopuscuspidatus 
Boriss (Shenxiangcao) and Irishalophila Pall (Yuanwei-
gen), is commonly used in Uygur medicine for the treat-
ment of asthma [13, 14]. Although the oral administration 
of Loki zupa decoction alleviates asthmatic symptoms, the 
exact mode of action of this drug has not been elucidated.
This study aims to investigate the effects of Loki zupa 
decoction on the inflammation of the airways in an oval-
bumin (OVA)-induced asthma mouse model.
Methods
Animals
Female BALB/c mice (6 weeks old) were purchased from 
Shanghai Sippr BK Laboratory Animal Co., Ltd (Shang-
hai, China) and raised in a pathogen-free rodent facility 
according to the procedures approved (2013-06-HSYY-
DJC-02; Additional file 1) by the Committee on the Ethics 
of Animal Experiments of Fudan University. The mice 
were housed in separate stainless steel cages (six mice 
per cage) in a temperature-controlled environment (20–
24 °C) on 12 h light–dark cycles with unrestricted access 
to food and water. All procedures of this study were in 
accordance with “Experimental Animal Ordinance” of 
Fudan University. The animal studies were performed fol-
lowing the ARRIVE guideline (Additional file 2).
Reagents
OVA and Mch were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).The Bio-Plex kit used in this study was 
purchased from Bio-Rad (Hercules, CA, USA). The roots of 
H. Boriss and I. Pall were provided by the Xinjiang Uygur 
Medical College Affiliated Hospital, China. Small samples 
of these herbs were identified [15–17] by experts at the 
Testing Center of Jiangyin Tianjiang Pharmaceutical Co., 
Ltd (Jiangyin, China), where samples were also deposited 
with the following voucher specimen numbers: LZ-2013-01 
to 02. Dexamethasone (DEX) was purchased from Chenxin 
pharmaceutical Co. Ltd (Jining, China) (Fig 1).
Preparation and extraction of a Loki zupa decoction
The roots of H. Boriss (250  g) and I. Pall (250  g) were 
decocted in water (3.6 L) for 1 h (two times). The decoc-
tion was then filtered through a sterile gauze and con-
centrated to 1000 mL (equivalent to 500 g of crude herb 
per 1000 mL of decoction) using a concentration heater. 
The concentrated decoction was subsequently diluted to 
several different concentrations (i.e., 14.0, 7.0 and 3.5 g of 
crude herb/kg body of weight) before being used.
For the extraction of the Loki zupa decoction, the 
roots of H. Boriss (1250  g) and I. Pall (1250  g) were 
ground into a fine powder using a pestle and mortar. The 
Fig. 1 Experimental protocol for the OVA-induced asthmatic model and treatment processes
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resulting powder was degreased with petroleum ether 
and extracted three times with 70  % ethanol. The com-
bined extracts were then filtered through sterile gauze 
and concentrated under vacuum on a rotary evaporator 
(EYELAN-1000, EYELA, Tokyo, Japan). The concen-
trated solution (predominantly aqueous) was extracted 
sequentially with petroleum ether, n-butanol and ethyl 
acetate. The water (LW), n-butanol (LN) and ethyl ace-
tate (LE) extracts of the Loki zupa decoction were diluted 
to a concentration equivalent to 7  g of crude herb/kg 
body weight before being used.
Asthmatic model establishment and treatment
Female BALB/c mice (n =  108) were arbitrarily divided 
into nine groups (n =  12 each group), including normal 
control (NC), asthma (A), Loki zupa decoction (L 14.0, 
L 7.0, L 3.5), LW, LN, LE and DEX groups. As shown in 
Fig.  1, mice in group A and the other treatment groups 
were sensitized with an intraperitoneal injection of 0.2 mL 
saline containing 20 μg OVA and 2 mg aluminum hydrox-
ide on days 0, 7, 14 and 21. From day 25, the mice in group 
A and the other treatment groups were challenged for 7 
consecutive days with a 3  % (w/v) OVA solution, which 
was administered using an ultrasonic nebulizer (402AI 
ultrasonic nebulizer, Yuyue, China). The mice in the NC 
group were sensitized and challenged with saline. From 
day 24, the mice in the NC and A groups were intragas-
trically administrated with saline, whereas the other treat-
ment groups were administrated with 14.0, 7.0 and 3.5 g/
kg Loki zupa decoctions and its extracts, as well as DEX.
Measurement of AHR to Mch
Twenty-four hours after their last OVA challenge, the 
mice were anesthetized with pentobarbital sodium 
(50  mg/kg) to allow for their AHR to be measured 
using an invasive approach, as described previously, 
using Buxco resistance and compliance measurements 
(FinePointe RC System, Buxco, Wilmington, NC, 
USA) [18]. Increasing doses of Mch (0, 3.125, 6.25 and 
12.5 mg/mL) were inhaled by nebulization to allow for 
the measurement of the AHR of the mice. Changes in 
airway resistance (RL) and lung dynamic compliance 
(Cdyn) were measured and these data were subse-
quently expressed as a percent change from the base-
line value.
Blood and bronchoalveolar lavage fluid (BALF) collection
Blood samples were collected from the mice immedi-
ately after the AHR measurements and stored at 4  °C 
for 2 h before being centrifuged at 5000×g for 15 min at 
4  °C (5804R, Eppendorf, Leipzig, Germany). The result-
ing serum was collected, repackaged and stored at –80 °C 
prior to being analyzed in a Bio-Plex assay (Bio-Plex 200 
System, Bio-Rad, Hercules, CA, USA). BALF collection 
was performed by lavaging the left lung with 0.3 mL ali-
quots of PBS (two times) through the tracheal cannula 
(total volume 0.6 mL). The resulting mixture was centri-
fuged at 1000×g for 10 min at 4 °C. The supernatant was 
collected and stored at –80 °C for further assay. The pel-
let from the BALF was resuspended in PBS (0.1 mL) for 
cell count and classification analysis using an automatic 
hematology analyzer (BC-5300 Vet, Mindray, China).
Pulmonary histopathology analysis
Samples of the lung tissues were collected, fixed in 4  % 
paraformaldehyde, embedded in paraffin and cut into 
5  μm sections for histopathological analysis. Lung sec-
tions were stained with hematoxylin and eosin (H&E) 
to evaluate any inflammatory changes. Ten mice from 
each group and six arbitrarily selected fields in each 
mouse were photographed using an optical microscope 
(ECLIPSE 80i, Nikon, Japan) and the resulting images 
were analyzed in detail. The severity of any inflamma-
tory cell infiltration in the lung samples was evaluated 
using a 5 point scoring system: 1, no cells; 2, a few cells; 
3, a ring of cells with a depth of one-cell layer; 4, a ring of 
cells with a depth of 2–4 cells; and 5, a ring of cells with 
a depth of >4 cells. The degree of airway inflammation in 
each group was determined by two independent analysts. 
If their results were different, a third analyst was consid-
ered for further analysis of the related data.
Inflammatory mediators assay in BALF and serum
Cytokines present in the BALF and serum, including 
IL-1β, TNF-ɑ, IFN-γ, IL-2, IL-4 and IL-5 were assayed by 
Bio-Plex according to the manufacturer’s instructions.
Real‑time quantitative PCR (qPCR) analysis
qPCR analysis of the cytokine expression levels in the 
lung samples collected from the mice was performed 
according to the manufacturer’s instructions. The total 
RNA isolated from the lung tissue in each group was 
reverse transcripted into the first strand of cDNA using 
the Trizol reagent and a RevertAid TM First Strand 
cDNA Synthesis Kit (Fermentas, Vilnius, Republic of 
Lithuania). The qPCR amplification experiments were 
subsequently performed according to the manufacturer’s 
instructions using a PCR Amplifier (ViiA7, life technolo-
gies, Carlsbad, CA, USA). The final data were normal-
ized to determine the level of GAPDH expression in each 
group, and the results were presented as fold changes 
compared with the expression levelsin mice belonging 
to the NC group. The primers’ sequences used for IL-4, 
IL-5, IL-13, IFN-γ and GAPDH are shown in Table 1.
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Statistical analysis
Data were expressed as the mean ±  standard deviation 
(SD). SPSS 19.0 for Windows (IBM, Chicago, Illinois, 
USA) was used to analyze the significance of the differ-
ences between the different groups, using 10 mice from 
each group. Statistical analysis of these data was per-
formed by one-way analysis of variance (ANOVA) for 
multiple comparisons followed by the least significantly 
different or Games-Howell test for a comparison of the 
different groups. P values less than 0.05 were considered 
statistically significant.
Results
Loki zupa decoction and its extracts treatment decreased 
AHR of OVA‑induced asthmatic mice
The results of this study showed that the short-term OVA 
challenge of mice with Mch led to a significant decrease 
in AHR in the RL group compared with mice in the NC 
group (P = 0.037, P = 0.003, P = 0.001; Fig. 2a). Treat-
ment of the mice with Loki zupa decoction or its extracts 
resulted in a significant decrease in the AHR of the RL 
group towards Mch compared with the OVA-induced 
asthmatic mice (P  <  0.05; Fig.  2a). Furthermore, the 
treatment of the mice with Loki zupa decoction and its 
extracts led to an obvious increase in their inhibitory 
effects towards Mch in the RL group. For example, at a 
Mch dose of 3.125  mg/mL, LE and DEX demonstrated 
significant inhibitory activity towards the RL group 
(P =  0.041, P =  0.047; Fig.  2a). Furthermore, all of the 
Loki zupa-and DEX-treated groupsled to a consider-
able decreasein AHR in the RLgroups at a Mch dose of 
6.25  mg/mL compared with OVA-induced asthmatic 
mice (P = 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, 
P < 0.001, P < 0.001). At aMch dose of 12.5 mg/mL, all 
of the treatment groups resulted in a significant decrease 
in AHR in the RL group compared with the asthmatic 
mice (P = 0.002, P < 0.001, P < 0.001, P < 0.001, P < 0.001, 
P  <  0.001, P  <  0.001; Fig.  2a). The L 3.5 and LE-treated 
groups showed the greatest inhibitory effect of all of the 
groups tested in the current study towards AHR in the RL 
group, which were the same as that of DEX at a Mch dose 
of 12.5 mg/mL (P = 0.364, P = 0.362; Fig. 2a).
Short-term OVA challenge in the mice also led to 
a significant reduction in Cdyn towards progressive 
doses of Mch compared with the mice in the NC group 
(P = 0.021, P = 0.002, P < 0.001; Fig. 2b). Treatment with 
Loki zupa decoction or its extracts resulted in improved 
Cdyn compared with the OVA-induced asthmatic mice. 
Furthermore, DEX treatment led to a dramatic increase 
in Cdyn compared with the asthmatic mice (P =  0.035, 
P = 0.004, P < 0.001). Different doses of Loki zupa decoc-
tion and its extracts resulted in a diverse range of effects 
on Cdyn to progressive doses of Mch. At a Mch dose of 
3.125  mg/mL, all three doses of the Loki zupa decoc-
tion treatment tested in the current study led to signifi-
cant increases in Cdyn (P = 0.031, P = 0.027, P = 0.032) 
compared with the asthmatic mice, representing a similar 
effect to that of DEX (P = 0.871, P = 0.329, P = 0.877). 
Table 1 Primer sequences used for qPCR amplification
Gene Primer sequence
IL-4 (NM_021283.2) Forward primer: 5′-CAGCAACGAAGAACACCACA-3′
Reverse primer: 5′-AATCCAGGCATCGAAAAGCC-3′
IL-5 (NM_010558.1) Forward primer: 5′-CAGTGTGAATGAGAGCCAGC-3′
Reverse primer: 5′-TTCTGTTGGCATGGGGTAGT-3′
IL-13 (NM_008355.3) Forward primer: 5′-TTGAGGAGCTGAGCAACA-3′
Reverse primer: 5′-CCATGCTGCCGTTGCA-3′






Fig. 2 Loki zupa decoction and its extracts decreased AHR in the 
OVA-induced asthmatic mice compared with the untreated mice. 
AHR towards progressive doses of Mch was measured by an invasive 
approach 24 h after the last OVA challenge. Changes in RL and Cdyn 
have been expressed as percentage changes from the correspond-
ing baseline values. The abbreviations for NC, A, L, LW, LN, LE, DEX are 
as follows: NC normal control, A asthma, L 14.0, L 7.0, L 3.5 Loki zupa 
decoction, LW water extract, LN n-butanol extract, LE ethyl acetate 
extract, DEX dexamethasone. *P < 0.05 vs. NC group, †P < 0.05 vs. A 
group, ‡P < 0.05 vs. DEX group
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At a Mch dose of 6.25 mg/mL, the L 14.0 and L 3.5 treat-
ment groups, as well as the LE treatment group, showed 
significant increases in Cdyn (P  =  0.010, P  =  0.012, 
P  =  0.017) compared with the asthmatic mice, which 
were similarto the effect of DEX (P = 0.630, P = 0.633, 
P = 0.513). At a Mch dose of 12.5 mg/mL, only the L 3.5 
and LE treatment groups showed significant increases in 
Cdyn (P  =  0.003, P  =  0.007) compared with asthmatic 
mice, with DEX treatment resulting in no significant 
changes (P = 0.693, P = 0.217).
Treatment with the Loki zupa decoction and its extracts 
attenuated pulmonary inflammation in the OVA‑induced 
asthmatic mice
Short-term OVA challenge led to significant increase in 
the infiltration of inflammatory cells into the peribron-
chiolar tissues (P < 0.001; Fig. 3). A pronounced increase 
in the level of mucus secretion and marked thickening 
of the basement-membrane were also observed in the 
bronchi of the OVA-induced asthmatic mice compared 
with the mice in the NC group. A reduction in inflamma-
tory infiltrates was observed in the mice treated with the 
Loki zupa decoction and its extracts, as well as the DEX 
treatment groups, compared with mice in the A group 
(P < 0.001). The LN and LE treatment groups were more 
effective in terms of their ability to alleviate inflammation 
compared with the L 7.0, L 3.5 and LW treatment groups 
(P < 0.001), and no significant differences were observed 
for the DEX treatment group (P = 0.062, P = 0.223).
Loki zupa decoction and its extracts treatment inhibited 
inflammatory cells in BALF of OVA‑induced asthmatic mice
The total white blood cell (WBC), neutrophil (Neu), lym-
phocyte (Lym), monocyte (Mon), eosinophil (Eos) and 
basocyte (Bas) counts in the BALF samples were ana-
lyzed to investigate the effects of the Loki zupa decoc-
tion and its extracts on the inflammatory cells in the 
lung tissue. OVA inhalation led to significant increases 
in the total WBC, Neu, Lym, Mon, Eos and Bas counts 
in the BALF samples (P =  0.001, P  <  0.001, P =  0.047, 
P < 0.001, P = 0.007, P = 0.041; Fig. 4). Treatment with 
Loki zupa decoction and its extracts, as well as DEX, led 
to a decrease in the total WBC (P =  0.013, P =  0.044, 
P = 0.009, P = 0.029, P = 0.001, P = 0.014, P = 0.004), 
Neu (P  =  0.001, P  =  0.001, P  =  0.001, P  =  0.047, 
P  <  0.001, P  =  0.003, P  =  0.001), Mon (P  <  0.001, 
P  <  0.001, P  <  0.001, P  =  0.001, P  <  0.001, P  <  0.001, 
P  <  0.001) and Eos (P  =  0.003, P  =  0.004, P  =  0.001, 
P = 0.047, P < 0.001, P = 0.004, P = 0.001) counts in the 
BALF samples. However, treatment with the Loki zupa 
decoction and DEX did not led to a decrease in the Lym 
(P = 0.519, P = 0.848, P = 0.543, P = 0.212, P = 0.089, 
P  =  0.273, P  =  0.133) or Bas (P  =  0.309, P  =  0.860, 
P = 0.337, P = 0.209, P = 0.123, P = 0.807, P = 0.631) 
counts in the BALF samples collected from the OVA-
induced asthmatic mice.
Loki zupa decoction and its extracts treatment 
regulated inflammatory cytokines in BALF and serum 
of OVA‑induced asthmatic mice
Marked increases were observed in the IL-1β 
(Fig.  5a,  P  =  0.042), TNF-α (Fig.  5b,P  =  0.045), IL-4 
(Fig. 5e, P = 0.038) and IL-5 (Fig. 5f, P = 0.002) levels in 
the BALF (Fig.  5) and serum (Fig.  6a,  P =  0.045, Fig.  6b, 
P = 0.042,  Fig. 6e, P = 0.008,  Fig. 6f, P = 0.047) (Fig. 6) sam-
ples collected from the OVA-induced asthmatic mice, as 
well as a decrease in their IFN-γ levels ( Fig. 5c, P = 0.039, 
Fig. 6c, P = 0.038). Treatment with the Loki zupa decoction 
or its extracts led to a reduction in the levels of IL-1β, TNF-
α, IL-4 and IL-5 in the BALF and serum samples, as well as 
an increase in IFN-γ levels (Fig. 5 or Fig. 6). 
The LN and LE treatment groups showed reduced lev-
els of IL-1β in their BALF samples (P = 0.039, P = 0.042; 
Fig.  5a) compared with the OVA-induced asthma mice. 
However, DEX was found to be ineffective for lowering 
the IL-1β levels in BALF (P =  0.466; Fig.  5a). The three 
different doses of Loki zupa decoction used in the cur-
rent study, as well as the LE and DEX treatment groups 
showed dramatic decreases in the TNF-α levels found 
in their BALF samples (P = 0.037, P = 0.043, P = 0.009, 
P  =  0.028, P  =  0.016; Fig.  5b) compared with A group. 
The L 3.5 and DEX treatment groups showed a tendency 
towards increased IFN-γ levels in their BALF samples, 
although these results were not statistically different 
(P = 0.247, P = 0.173; Fig. 5c). The L 14.0, L 3.5, LN and 
DEX treatment groups showed reduced IL-2 levels in their 
BALF sampled (P = 0.049, P = 0.019, P = 0.019, P = 0.023; 
Fig.  5d) compared with A group. The L 14.0 treatment 
group showed a decrease in the IL-4 levels in its BALF 
sampled (P = 0.047; Fig. 5e) compared with A group. Fur-
thermore, the L 3.5 and LW treatment groups showed 
reduced levels of IL-5 compared with the OVA-induced 
asthmatic mice (P = 0.004, P = 0.004; Fig. 5f). However, 
treatment with DEX had no effect on the IL-4 and IL-5 
levels in the BALF samples of the mice in A group.
The L 14.0, L 7.0, LN and LE treatment groups showed 
significant decreases in the IL-1β levels observed in the 
serum samples taken from the OVA-induced asthmatic 
mice (P = 0.044, P = 0.045, P = 0.049, P = 0.047; Fig. 6a) 
compared with mice in A group. However, DEX treat-
ment did not result in a significant decrease in IL-1β lev-
els in the serum (P = 0.63; Fig. 6a). The L 7.0, LN, LE and 
DEX treatment groups showed significant decreases in 
the TNF-α levels of the serum samples collected from the 
asthmatic mice (P = 0.001, P = 0.01, P < 0.001, P = 0.012; 
Fig.  6b) compared with the mice from the untreated 
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group. The LE and DEX treatment groups showed a sig-
nificant increase in the IFN-γ levels of the serum sam-
ples compared with the OVA-induced asthmatic mice 
(P < 0.001, P = 0.03; Fig. 6c). Moreover, LE treatment was 
found to be more effective than DEX for promoting the 
levels of IFN-γ in serum (P = 0.001). None of the treat-
ment groups tested in the current study had a discern-
ible impact on the levels of IL-2 secretion in the serum 
(Fig.  6d). However, the LW and DEX treatment groups 
showed a marked decrease in the IL-4 levels of the serum 
Fig. 3 Loki zupa decoction and its extracts attenuated airway inflammation of OVA-induced asthmatic mice. The airway inflammatory changes in 
each group were assessed by H&E staining of the lung slices and examined at 10× magnification by light microscopy. At least ten mice in each 
group and six arbitrarily selected fields in each mouse were assessed. Inflammatory scores in each group were assessed. Bar = 500 μm. *P < 0.05 vs. 
NC group, †P < 0.05 vs. A group, ‡P < 0.05 vs. DEX group
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(P = 0.021, P = 0.049; Fig. 6e) compared with A group. 
Lastly, the serum samples collected from the L 14.0, LW 
and LE treatment groups showed significant reductions 
in the secretion of IL-5 (P = 0.036, P = 0.04, P = 0.049; 
Fig.  6f ) compared with the untreated mice. However, 
DEX exhibited no inhibitory activity towards the IL-5 
levels in serum.
Treatment with Loki zupa decoction or its extracts 
regulated mRNA expression of Th2 and Th1 cytokines 
in OVA‑induced asthmatic mice
OVA inhalation led to enhanced levels of IL-4  (Fig.  7b), 
IL-5 (Fig. 7c) and IL-13 (Fig. 7d) mRNA expression, as well 
as reduced levels of IFN-γ (Fig.  7a) mRNA expression in 
the OVA-induced asthmatic mice compared with mice in 
the NC group (P < 0.001, P = 0.045, P = 0.049, P = 0.047; 
Fig.  7). Treatment with the Loki zupa decoction or its 
extracts led to reduced IL-4  (Fig.  7b)  , IL-5 (Fig.  7c) and 
IL-13 (Fig. 7d) mRNA expression levels in asthmatic mice, 
as well as improved IFN-γ(Fig 7a)  mRNA expression. With 
the exception of the L 7.0 group, all of the other treatment 
groups exhibited a significant promotion effect towards the 
mRNA expression of IFN-γ (P = 0.039, P = 0.04, P = 0.048, 
P = 0.035, P < 0.001, P < 0.001; Fig. 7a). The L 3.5, LN and 
LE treatment groups also showed a dramatic decrease 
in the mRNA expression of IL-4 (P  =  0.021, P  =  0.023, 
P  =  0.017; Fig.  7b). Furthermore, mice in the L 3.5, LW 
and LE treatment groups demonstrated a marked reduc-
tion in their IL-5 mRNA expression (P = 0.043, P = 0.044, 
P = 0.04; Fig. 7c). The L 7.0, LN and LE treatment groups 
led to an obvious decrease in the mRNA expression of 
IL-13 (P < 0.001, P = 0.037, P = 0.046; Fig. 7d). DEX treat-
ment had no effect on the mRNA expression levels of IL-4, 
IL-5 and IL-13 in our study (P = 0.91, P = 0.83, P = 0.792).
Discussion
Several characteristic features of acute asthma are 
observed in the OVA-induced mice asthma model, 
including an exaggerated airway response to Mch and 
eosinophil-rich airway inflammation [19]. Short-term 
OVA inhalation resulted in a marked increase in RL, as 
well as a pronounced decrease in Cdyn towards increas-
ing doses of Mch. H&E staining of the lung slices revealed 
that there was a significant increase in the infiltration 
of Eos into the airways of the asthmatic mice, as well as 
the levels of mucus secretion. Treatment with Loki zupa 
decoction led to a dramatic decrease in the elevated AHR 
towards progressive Mch doses in asthmatic mice. Fur-
thermore, the L 3.5 and LE treatment groups showed a 
reduction in RL, which was almost identical to that of 
DEX, highlighting the potential value of these materi-
als for the treatment of asthma. Treatment withthe Loki 
zupa decoction resulted in a decrease in the number of 
WBC, Neu, Eos and Mon cell counts in the lungs of the 
asthmatic mice. There was a direct correlation between 
Eos counts and asthma symptom scores [20]. According 
to the results of several previous studies [21, 22], treat-
ments aimed at reducing airway eosinophilia numbers 
are effective for controlling asthma symptoms. Treatment 
with the Loki zupa decoction also had a direct impact on 
Eos numbers in the airways, highlighting its efficacy for 
controlling asthma.
In our study, Loki zupa decoction exerted prominent 
inhibitory effects towards the levels of IL-1β and TNF-α. 
Elevated Th2 cell levels and cytokine functions are char-
acteristic features of allergic asthma, which have been 
implicated in eosinophilic inflammation as well as AHR 
[5, 23, 24]. The administration of L 14.0 and LW resulted 
in a dramatic reduction in IL-4 levels in the BALF and 
serum samples collected from the asthmatic mice. IL-4 is 
essential for the development of AHR in murine models 
[25, 26], indicating that the decrease observed in AHR 
following the treatment of the mice with Loki zupa decoc-
tion could be attributed to a reduction in IL-4 levels. IL-5 
is involved in Eos maturation, differentiation, recruit-
ment, and survival [6]. L 3.5 and LW, as well as L 14.0 and 
LE inhibited the OVA-induced increase in IL-5 levels in 
the BALF and serum samples collected from the mice. 
However, DEX had no effect on the levels of IL-4 and 
IL-5 in the BALF samples or the IL-5 levels in the serum 
samples. Th2 blockade is effective for suppressing the fea-
tures of allergic disease in mice [27]. Anti-IL-5 antibody 
has therefore been reported to reduce the risk of exacer-
bation in patients with severe eosinophilic asthma [28]. 
Approximately 50  % of asthmatic patients have a Th2-
driven phenotype [29]. The treatment of the mice with 
Loki zupa decoction inhibited the expression of the Th2 
cytokines, indicating that its related anti-asthmatic effect 
Fig. 4 Loki zupa decoction and its extracts inhibited the inflamma-
tory cells in BALF. The total white blood cell (WBC), neutrophil (Neu), 
lymphocyte (Lym), monocyte (Mon), eosinophil (Eos) and basocyte 
(Bas) counts in BALF were analyzed and the resulting data expressed 
as the mean ± SD. * P < 0.05 vs. NC group, †P< 0.05 vs. A group
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could be attributed to its ability to inhibit the activity of 
the Th2 cells. Treatment with Loki zupa decoction or its 
extracts also led to a significant down-regulatory effect 
on the gene amplification levels of IL-4, IL-5 and IL-13. 
However, DEX treatment had no discernible impact on 
the levels of these cytokines. IL-13 is a key Th2 cytokine 
that might be involved in the development of asthma [30, 
31]. Transgenic mice over-expressing IL-13 in their lung 
develop some of the features of airway inflammation typ-
ically observed in asthma [32]. Treatment with L 7.0, LN 
and LE led to a remarkable decrease in the mRNA ampli-
fication of IL-13, indicating that the anti-inflammatory 
Fig. 5 Loki zupa decoction and its extracts regulated the secretion of several inflammatory cytokines in BALF. The IL-1β, TNF-α, IFN-γ, IL-2, IL-4 and 
IL-5 levels in BALF were measured by Bio-Plex and the resulting data expressed as mean ± SD. a IL-1β level in BALF, b TNF-α level in BALF, c IFN-γ 
level in BALF, d IL-2 level in BALF, e IL-4 level in BALF, f IL-5 level in BALF. *P < 0.05 vs. NC group, †P < 0.05 vs. A group
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effects of these materials could be related to their ability 
to inhibit the expression of this cytokine.
Th1 cells have been reported to exhibit inhibitory 
effects towards the inflammation of asthmatic air-
ways by inhibiting Th2 cytokine responses [33]. Fur-
thermore, there are generally lower levels ofthe Th1 
cytokine IFN-γ in asthma [34, 35]. The treatment of the 
mice with Loki zupa decoction or its extracts and DEX 
effectively promoted the expression of IFN-γ at the 
gene and protein levels. This result therefore indicated 
that the anti-inflammatory activity of Loki zupa decoc-
tion towards asthma could be attributed to its ability to 
promote the activity of Th1 cells, as well as its antago-
nistic potential towards the function of Th2 cells. IFN-γ 
Fig. 6 Loki zupa decoction and its extracts regulated the secretion of several inflammatory cytokines in serum. The IL-1β, TNF-α, IFN-γ, IL-2, IL-4 
and IL-5 levels in serum were measured by Bio-Plex and the resulting data expressed as mean ± SD. a IL-1β level in serum, b TNF-α level in serum, 
c IFN-γ level in serum, d IL-2 level in serum, e IL-4 level in serum, f IL-5 level in serum. *P < 0.05 vs. NC group,†P < 0.05 vs. A group, ‡P < 0.05 vs. DEX 
group
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has been shown to inhibit antigen-induced AHR in 
mice [36], indicating that elevated levels of IFN-γ might 
be involved in the responses observed in the Loki zupa 
decoction-treated groups.
Except for the decrease observed in the serum level of 
IL-4, DEX promoted the expression of the Th1 cytokine 
IFN-γ in the serum and lung tissue samples, but did not 
lead to a decrease in the expression levels of IL-4 and IL-5 
in BALF. In contrast, Loki zupa decoction exhibited inhib-
itory activity towards the expression of IL-4 and IL-5 in 
the BALF and serum samples, as well as the lung tissues. 
However, Loki zupa decoction also exhibited a significant 
promotion effect towards IFN-γ, indicating that the anti-
inflammatory effect of the Loki zupa decoction treatment 
could be attributed to the promotion and suppression of 
the Th1 and Th2 cytokine expression levels, respectively. 
This promotion of the Th1 cell function could therefore be 
responsible for the effect of DEX on asthma.
The JAK-STAT pathway promotes the differentiation of 
naive T cells into Th2 cells, as well as inducing the secre-
tion of Th2 cytokines [37–39]. STAT4 has been implicated 
in IL-12-dependent Th1 cellular responses, and mice lack-
ing STAT4 have been reported to show severe deficiencies 
in mounting a Th1 response [40]. Furthermore, IL-4-in-
duced STAT6 activation has been reported to contribute 
to the differentiation of Th2 cells [41]. The JAK-STAT 
pathway could therefore be involved in regulating the 
Th1/Th2 imbalance observed in asthma patients following 
their treatment with Loki zupa decoction.
Conclusion
The treatment of mice with Loki zupa decoction and its 
extracts resulted in a decrease in AHR and attenuated 
airway inflammation in an OVA-induced asthma mouse 
model by promoting and suppressing the cellular func-
tions of Th1 and Th2, respectively.
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Fig. 7 Loki zupa decoction and its extracts inhibited and promoted the Th2 and Th1 cytokine mRNA expression levels of asthmatic mice, respec-
tively. The mRNA expression levels of IL-4, IL-5, IL-13 and IFN-γ in the lung tissues were measured by qPCR and the data expressed as the mean ± SD. 
a mRNA expression level of IFN-γ, b mRNA expression level of IL-4, c mRNA expression level of IL-5, d mRNA expression level of IL-13. *P < 0.05 vs. NC 
group, †P < 0.05 vs. A group
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